Novartis CEO feels heat on U.S. generics, Cosentyx drop

ZURICH (Reuters) – Swiss drugmaker Novartis’ first quarterly results under new CEO Vas Narasimhan have been marred by a prized psoriasis treatment that disappointed and a sharp slump in sales by its U.S. generics unit.


Source: Reuters Medical News

Leave a Reply

Your email address will not be published. Required fields are marked *